NCT03416387

Brief Summary

Three-dimensional (3D) printing has gained popularity in medicine over the last decade. Once 3D printers have become more affordable, the true strength of this technique has been recognized because of its ability to obtain anatomical models based on the unique characteristics of each patient. Liver resections are challenging operations because of the complex nature of the liver and venous anatomy within the liver, so 3D imaging is a promising new tool for surgical planning.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 23, 2017

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 23, 2017

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

December 19, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 31, 2018

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

January 31, 2018

Status Verified

January 1, 2018

Enrollment Period

Same day

First QC Date

December 19, 2017

Last Update Submit

January 30, 2018

Conditions

Keywords

complex liver surgery3D printing

Outcome Measures

Primary Outcomes (1)

  • Surgical planing

    Number of Participants susceptible of complex liver surgery as assessed by 3D printing and 3D digital image reconstruction, change from the baseline to the surgical strategy

    2 weeks

Secondary Outcomes (2)

  • Teaching for students and residents

    1 day

  • Understanding of surgery by the patient

    1day

Study Arms (1)

OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION

OTHER
Device: 3D PRINTING

Interventions

A 3D digital image reconstruction and a 3D printing model were performed in all patients with complex liver tumors.

OTHER: 3D PRINTING AND 3D DIGITAL IMAGE RECONSTRUCTION

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Complex liver tumors (bilobar disease, infiltration of suprahepatic veins or requiring two-time resection or intrahepatic vascular reconstruction).
  • Preoperatively was performed, a CT scan and / or MRI of all patients were performed to document the tumor distribution, estimate remaining liver volume, and identify tumor-vessel relationships in order to know the intraoperative vascular anatomy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinic and University Virgen de la Arrixaca Hospital

Murcia, Spain

RECRUITING

MeSH Terms

Conditions

Liver Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Central Study Contacts

Victor Lopez Lopez, FEA

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Profesor

Study Record Dates

First Submitted

December 19, 2017

First Posted

January 31, 2018

Study Start

June 23, 2017

Primary Completion

June 23, 2017

Study Completion

June 1, 2018

Last Updated

January 31, 2018

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will share

Good practice principles include: (i) the use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access; (ii) seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and (iii) establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD.

Locations